Related Experiment Videos
Decrease in mortality rate of chronic obstructive pulmonary disease (COPD) with statin use: a population-based
Wataru Ishida1, Takashi Kajiwara, Mototsugu Ishii
1Department of Diabetes and Metabolism, Iwate Medical University, Morioka, Japan.
The Tohoku Journal of Experimental Medicine
|June 27, 2007
Summary
Statins, cholesterol-lowering drugs, significantly reduce mortality from cardiovascular diseases and chronic obstructive pulmonary disease (COPD). This population-based study suggests broader health benefits beyond heart health.
Area of Science:
- Pharmacology
- Epidemiology
- Public Health
Background:
- Statins (HMG-CoA reductase inhibitors) are established cardiovascular disease (CVD) mortality reducers.
- Pleiotropic effects (anti-inflammatory, anti-oxidative) suggest potential benefits beyond lipid-lowering.
- Limited research exists on statin impact on non-cardiovascular diseases.
Purpose of the Study:
- To investigate the association between statin sales and mortality rates from various causes in Japan.
- To explore potential beneficial effects of statins on diseases beyond cardiovascular conditions.
Main Methods:
- Population-based analysis utilizing Japanese marketing data on statin sales.
- Comparison of per capita statin sales in the elderly population (>65 years) with mortality data across 47 prefectures.
- Statistical correlation analysis between statin sales and mortality from major causes of death.
Main Results:
- Significant negative correlation observed between statin sales per capita and cardiovascular disease mortality (p < 0.05).
- Statin sales correlated with decreased mortality from COPD (p < 0.0001), senility (p < 0.01), pneumonia (p < 0.05), accidents (p < 0.05), and all-cause mortality (p < 0.05).
- No significant association found between statin sales and mortality from renal failure, liver diseases, suicide, or malignant diseases.
Conclusions:
- Statin use is associated with reduced mortality not only from cardiovascular diseases but also from COPD and other causes.
- Findings suggest a broad spectrum of beneficial effects of statins.
- Prospective randomized clinical trials are warranted to confirm the protective effect of statins on COPD.
Related Concept Videos
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:26Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:24Chronic Obstructive Pulmonary Disease
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History